Trending

EUSA Pharma

Record number of health firms feature in UK top 100 private tech list

Record number of health firms feature in UK top 100 private tech list

A record number of health and medtech companies have been included in the Sunday Times Sage Tech Track

X

Record number of health firms feature in UK top 100 private tech list

https://pharmaphorum.com/news/babylon-among/

EUSA Pharma buys rights to Janssen rare disease drug

EUSA Pharma buys rights to Janssen rare disease drug

UK-based EUSA Pharma has bought worldwide rights to Janssen’s rare diseases drug Sylvant (siltuximab) for $115 million. EUSA

X

EUSA Pharma buys rights to Janssen rare disease drug

https://pharmaphorum.com/news/eusa-pharma-buys-rights-to-janssen-rare-disease-drug/

Taking lenient stance, NICE backs neuroblastoma drug

Taking lenient stance, NICE backs neuroblastoma drug

Body makes special case due to rarity of the disease

X

Taking lenient stance, NICE backs neuroblastoma drug

https://pharmaphorum.com/news/taking-lenient-stance-nice-backs-neuroblastoma-drug/

Fotivda approved in Scotland for kidney cancer

Fotivda approved in Scotland for kidney cancer

The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma’s kidney cancer drug Fotivda, enabling

X

Fotivda approved in Scotland for kidney cancer

https://pharmaphorum.com/news/fotivda-scotland-kidney-cancer/

NICE asks EUSA pharma to drop price of neuroblastoma drug

NICE asks EUSA pharma to drop price of neuroblastoma drug

NICE calls for price cut before possible CDF funding

X

NICE asks EUSA pharma to drop price of neuroblastoma drug

https://pharmaphorum.com/news/nice-asks-eusa-pharma-to-drop-price-of-neuroblastoma-drug/

EUSA Pharma’s Fotivda approved in EU for kidney cancer

EUSA Pharma’s Fotivda approved in EU for kidney cancer

UK pharma gets licence for second cancer drug

X

EUSA Pharma’s Fotivda approved in EU for kidney cancer

https://pharmaphorum.com/news/eusa-pharmas-fotivda-approved-eu-kidney-cancer/

EUSA Pharma looks to further in-licensing to build growth

EUSA Pharma looks to further in-licensing to build growth

Specialist company EUSA Pharma is looking for new medicines to develop after getting two cancer drugs recommended by European

X

EUSA Pharma looks to further in-licensing to build growth

https://pharmaphorum.com/news/uks-eusa-pharma-looks-bolster-pipeline/

Regulators finally back Merck KGaA oral MS drug

Regulators finally back Merck KGaA oral MS drug

A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green

X

Regulators finally back Merck KGaA oral MS drug

https://pharmaphorum.com/news/regulators-mavenclad/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com